Clinical Trials Logo

Visual Fields Hemianopsia clinical trials

View clinical trials related to Visual Fields Hemianopsia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05525949 Completed - Clinical trials for Hemianopsia, Homonymous

Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Start date: October 19, 2022
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain. The other half will not receive any training because there is no standard treatment for visual field defect caused by brain disease.

NCT ID: NCT04102605 Completed - Clinical trials for Hemianopsia, Homonymous

Visual Perceptual Learning for the Treatment of Visual Field Defect

VIVID2
Start date: October 17, 2019
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain damage. Half of participants will receive visual perceptual training using the Nunap Vision, while the other half will receive sham training using the Nunap Vision-C.

NCT ID: NCT04021160 Completed - Stroke, Ischemic Clinical Trials

Repetitive Transcranial Magnetic Stimulation for Post-Stroke Visual Field Defects

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Visual field defects (VFD) usually do not show improvement beyond 12 weeks from onset. Plasticity occurs in areas of residual vision (ARV) at the visual field which are the functional counterpart of partially damaged brain regions at the areas around brain lesion. Few treatment options are currently available for post-stroke VFD. In this pilot study, the effect of repetitive transcranial magnetic stimulation (rTMS) applied to these areas on VFD in patients with cortical infarction will be studied. Patients will be divided into two groups; an active group which will receive active stimulation and a sham group which will receive placebo stimulation through a sham coil.